

VOLATILE FINGERPRINTING OF PSEUDOMONAS AERUGINOSA AND RESPIRATORY SYNCYTIAL VIRUS INFECTION IN AN INVITRO CYSTIC FIBROSIS COINFECTION MODEL

Giorgia Purcaro¹, Christiaan A Rees², Jeffrey A Melvin³, Jennifer M Bomberger³ and Jane E Hill^{1,2}

¹ *Thayer School of Engineering, Dartmouth College, Hanover, NH, 03755, United States of America*

² *Geisel School of Medicine, Dartmouth College, Hanover, NH, 03755, United States of America*

³ *Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, 15219, United States of America*

E-mail: Jane.E.Hill@dartmouth.edu

Abstract

Volatile molecules in exhaled breath represent potential biomarkers in the setting of infectious diseases, particularly those affecting the respiratory tract. In particular, *Pseudomonas aeruginosa* is a critically important respiratory pathogen in specific subsets of the population, such as those with cystic fibrosis (CF). Infections caused by *P. aeruginosa* can be particularly problematic when co-infection with respiratory syncytial virus (RSV) occurs, as this is correlated with the establishment of chronic *P. aeruginosa* infection. In the present study, we evaluate the volatile metabolites produced by *P. aeruginosa* (PAO1)-infected, RSV-infected, co-infected, or uninfected CF bronchial epithelial (CFBE) cells, in vitro. We identified a volatile metabolic signature that could discriminate between *P. aeruginosa*-infected and non-*P. aeruginosa*-infected CFBE with an area under the receiver operating characteristic curve (AUROC) of 0.850, using the machine learning algorithm random forest (RF). Although we could not discriminate between RSV-infected and non-RSV-infected CFBE (AUROC = 0.431), we note that sample classification probabilities for RSV-infected cell, generated using RF, were between those of uninfected CFBE and *P. aeruginosa*-infected CFBE, suggesting that RSV infection may result in a volatile metabolic profile that shares attributes with both of these groups. To more precisely elucidate the biological origins of the volatile metabolites that were discriminatory between *P. aeruginosa*-infected and non-*P. aeruginosa*-infected CFBE, we measured the volatile metabolites produced by *P. aeruginosa* grown in the absence of CFBE. Our findings suggest that the discriminatory metabolites produced likely result from the interaction of *P. aeruginosa* with the CFBE cells, rather than the metabolism of media components by the bacterium. Taken together, our findings support the notion that *P. aeruginosa* interacting with CFBE yields a particular volatile metabolic signature. Such a signature may have clinical utility in the monitoring of individuals with CF.

Keywords:

cystic fibrosis, respiratory syncytial virus (RSV), *Pseudomonas aeruginosa*, VOCs, metabolomics, comprehensive two-dimensional gas chromatography (GC×GC), mass spectrometry

Supplementary material for this article is available [online](#)

1. Introduction

Respiratory tract infections are among the leading causes of death worldwide, resulting in 3.2 million deaths in 2015 alone [1], and pneumonia remains one of the world's leading causes of death for children under the age of five [2]. According to the Etiology of Pneumonia in the Community study conducted by Centers for Disease Control and Prevention, human rhinovirus (9%), influenza virus (6%), and *Streptococcus pneumoniae* (5%) are the most prevalent pathogenic agents in the adult population, while respiratory syncytial virus (RSV) (28%) and human rhinovirus (27%) are the predominant pathogens in children [3, 4]. In this study, polymicrobial infections (i.e., infections caused by more than one pathogen) were identified in 36% of adults and 81% of children, with the occurrence of poly microbial infections resulting in substantially worse morbidity and mortality [5–8]. Of particular interest are viral-bacterial polymicrobial infections, as viral infections have been shown to promote bacterial colonization of the airway up to several weeks following initial infection [9–13].

Polymicrobial infections involving influenza virus and *S. pneumoniae* are commonly encountered in the human population [10]. However, other viral-bacterial interactions may occur in specific subsets of the population, such as in the setting of cystic fibrosis (CF). In CF, a complex and dynamic respiratory microbiota interacts and evolves in a way that is not fully characterized to-date [14]. In this population, coinfection of respiratory viruses and *Pseudomonas aeruginosa* is correlated with the establishment and exacerbation of chronic *P. aeruginosa* lung infection [15–20], with RSV as the etiological agent in 9%–58% of viral infections in these patients [21]. Chronic *P. aeruginosa* infection has dire health consequences in these individuals, including decreased quality of life and reduced life expectancy [22]. It has been demonstrated that the antiviral interferon host response to RSV, along with the release of transferrin-bound iron that occurs during viral infection, promotes *P. aeruginosa* biofilm formation, and this, in turn, can be correlated with disease exacerbation [23].

Volatile molecules have been investigated as potential biomarkers for the diagnosis of both acute and chronic respiratory infections [24]. Numerous studies have focused on the volatile metabolic fingerprints generated by bacterial infections *in vivo* [25–31], but none have evaluated the ability of this approach to discriminate between virally and bacterially derived volatile compounds, nor deconvolute bacterial- and viral-associated signatures in the setting of a polymicrobial environment. Nevertheless, several transcriptomics studies have demonstrated that viral and bacterial infections induce distinct responses by host cells [32–42]. Such findings provide the rationale behind our hypothesis that volatile metabolic signatures can be used to differentiate between virally-infected, bacterially-infected, and co-infected cells. The aim of this study is thus to investigate the ability of volatile metabolites to discriminate between respiratory epithelium infected, *in vitro*, with *P. aeruginosa* and RSV singularly, and to evaluate the polymicrobial fingerprint generated by the infection of *P. aeruginosa* and RSV simultaneously. For this, we employ solid-phase microextraction (SPME) followed by comprehensive two-dimensional gas chromatography (GC × GC) with a time-of-flight mass spectrometer (TOF MS), a powerful technique for the analysis of complex mixtures.

2. Materials and methods

2.1. Viral and bacterial infection sample preparation

Cell culture: Immortalized homozygous CFTR Δ F508 CFBE410- human bronchial epithelial cells (CFBE) were maintained in a humidified incubator at 37 °C 5% CO₂ in minimum essential medium (MEM) containing phenol red (Gibco, Waltham, MA, United States) supplemented with 10% fetal bovine serum (FBS, Gemini Bio-Products, West Sacramento, CA, United States), 0.5 μ g mL⁻¹ Plasmocin prophylactic (InvivoGen, San Diego, CA, United States), 2 mM L-glutamine, 5 U mL⁻¹ penicillin, and 5 μ g mL⁻¹ streptomycin (Sigma-Aldrich, St. Louis, MO, United States) [23]. Immortalized STAT1^{-/-} NY3.2 mouse fibroblasts were maintained in MEM containing phenol red supplemented with 5% FBS, 5 U mL⁻¹ penicillin, and 5 μ g mL⁻¹ streptomycin. Both cell types are not on the commonly misidentified list, and cells were tested quarterly for mycoplasma using a Southern Biotech mycoplasma detection kit. CFBE410- cells were seeded at near confluency on 12 mm diameter, 0.4 μ m pore size Transwell permeable polycarbonate membrane supports (Costar, St. Louis, MO, United States). After attachment and confluency, epithelial cells were differentiated at air-liquid interface (ALI) for one week. RSV line A2 was propagated in NY3.2 cells. RSV was extracted and stored in high salt media (HSM) at -80 °C. Plaque-forming units were determined by immunoreactive staining assay in NY3.2 cells. *P. aeruginosa* strain PAO1 was grown in Lysogeny Broth (LB) at 37 °C on a roller.

P. aeruginosa-only samples: Bacteria were prepared by washing an overnight culture in MEM supplemented with 2 mM L-glutamine and culturing in MEM supplemented with 2 mM L-glutamine in a 25 cm² cell culture flask (Corning, Corning, NY, United States) at 37 °C 5% CO₂ for 24 h. Media was then transferred to a tube and centrifuged to remove bacterial aggregates. Clarified media was filtered through a 0.22 μ m filter (Merck Millipore, Burlington, MA, United States) and stored at -80 °C. The same set up was used without *P. aeruginosa* inoculation for media-only controls.

Bacterial-epithelial co-cultures: ALI-differentiated CFBE410- cells were washed with MEM lacking phenol red (Gibco) supplemented with 2 mM L-glutamine, and basolateral media was replaced with MEM containing phenol red supplemented with 10% FBS and 2 mM L-glutamine. Cells were inoculated with RSV at a multiplicity of infection (MOI) of 1 in MEM supplemented with 2 mM L-glutamine in the apical compartment. Control cells were inoculated with MEM containing an equal volume of vehicle (HSM). Apical media was removed after infection and cells were returned to ALI and maintained in antibiotic-free basolateral media. RSV-infected cells were then inoculated with *P. aeruginosa* that was prewashed in MEM lacking phenol red supplemented with 2 mM L-glutamine at an MOI of approximately 25. After 1 h attachment, non-attached bacteria were removed and apical media was adjusted to 0.4% L-arginine. After an additional 5 h, apical media was transferred to a tube and epithelium-associated biofilms were disrupted in 0.1% Triton X-100 (Bio-Rad, Hercules, CA, United States) and analyzed by serial dilution and plating on LB agar for colony-forming units. Apical media was centrifuged to remove bacterial aggregates, passed through a 0.22 μ m filter, and stored at -80 °C. RNA was collected from a separate set of Transwells by RNeasy with QIAshredder columns (Qiagen, Hilden, Germany) according to manufacturer recommendations. Transcript levels for GAPDH, the RSVN gene, and IFNL1 were assessed by converting RNA into cDNA with iScript cDNA Synthesis Kit and performing RT-qPCR using iQ SYBR Green Supermix (Bio-Rad) on a StepOne Real-Time PCR System (ThermoFisher Scientific, Waltham, MA, United States). Primers were as follows: for GAPDH (5'-CGACCACTTTGTCAAGCTCA-3', 5'-AGGGGAGATTCAAGTGTGGTG-3'), for RSV N gene (5'-CGCCTTGAAGAGTCACTCA-3', 5'-GAAGCCTCAGGTCCCAATTC-3'), and for IFNL1 (5'-GCTCTT AGCAAAGTCAAGTTGAATGA-3', 5'-

TGCTCCGTT GGATGGTGTATT-3'). Conditions analyzed were epithelial cells alone, RSV-infected epithelial cells, *P. aeruginosa*-infected epithelial cells, and co-infected epithelial cells.

2.2. Sample preparation for volatile metabolites analysis

Five-hundred μL of filtered apical media were collected into a 10 mL air-tight glass vial sealed with a PTFE/silicone cap (Sigma-Aldrich) frozen at $-20\text{ }^{\circ}\text{C}$ until analysis (within one month of collection). Samples were incubated for 15 min (the equilibration phase) at $37\text{ }^{\circ}\text{C}$ before fiber exposure for 45 min at the same temperature (the extraction phase). Samples were agitated at 250 rpm during both the equilibration and extraction phases. A divinylbenzene/carboxen/ polydimethylsiloxane (DVB/CAR/PDMS) $d_f 50/ 30\ \mu\text{m}$, 2 cm length fiber (Supelco, Bellefonte, PA, USA) was used to pre-concentrate the volatile molecules. The fiber was then introduced into the GC injector for thermal desorption for 1 min at $250\text{ }^{\circ}\text{C}$ in splitless mode. The fiber was conditioned before use and baked-out after each run for 7 min at $250\text{ }^{\circ}\text{C}$. Absence of carryover was verified by desorbing the fiber into the GC injector after the baking time.

2.3. Analytical instrumentation

The analyses of volatile molecules were carried out using a Pegasus 4D (LECO Corp., St. Joseph, MI, United States) GC \times GC TOF MS instrument with an Agilent 6890 GC, and equipped with an MPS autosampler (Gerstel, Linthicum Heights, MD, United States). The first dimension column was an Rxi-624Sil ($60\ \text{m} \times 250\ \mu\text{m} \times 1.4\ \mu\text{m}$ (length \times internal diameter \times film thickness)) connected in series with a Stabilwax secondary column ($1\ \text{m} \times 250\ \mu\text{m} \times 1.4\ \mu\text{m}$), both from Restek (Bellefonte, PA, USA). The carrier gas was helium, at a flow rate of $2\ \text{ml min}^{-1}$. The primary oven temperature program was $35\text{ }^{\circ}\text{C}$ (hold 1 min) ramped to $230\text{ }^{\circ}\text{C}$ at a rate of $3.5\text{ }^{\circ}\text{C min}^{-1}$. The secondary oven and the thermal modulator were offset from the primary oven by $+5\text{ }^{\circ}\text{C}$ and $+25\text{ }^{\circ}\text{C}$, respectively. A modulation period of 2.0 s (alternating 0.5 s hot and 0.5 s cold pulses) was used. The transfer line temperature was set at $250\text{ }^{\circ}\text{C}$. A mass range of m/z 30–500 was collected at a rate of 200 spectra s^{-1} following a 2.5 min acquisition delay. The ion source was maintained at $200\text{ }^{\circ}\text{C}$. Data acquisition and analysis were performed using ChromaTOF software, version 4.50 (LECO Corp.).

2.4. Processing and analysis of chromatographic data

Chromatographic data were processed and aligned using ChromaTOF. A signal-to-noise cutoff was set at 50:1 in at least one chromatogram and a minimum of 20:1 s N^{-1} ratio in all others. For the alignment of peaks across chromatograms, maximum first and second-dimension retention time deviations were set at 6 s and 0.2 s, respectively, and the inter-chromatogram spectral match threshold was set at 600 (out of 1000). Compounds eluting prior to 4 min and artifacts were removed prior to statistical analysis. Artifacts were identified by running a series of instrument blanks (i.e., runs without SPME fiber injections) and fiber blanks (i.e., runs with SPME fiber injections but without fiber headspace exposure) to identify the compounds deriving from column and fiber bleeding (e.g., siloxane, silanol, etc). Furthermore, the most common and ubiquitous plasticizers (i.e. phthalates) were removed as well.

A mixture of normal alkanes ($\text{C}_6\text{--C}_{20}$) was analyzed every 20 runs to calculate the linear retention index (LRI) [43] and evaluate the instrument performance. The SPME and GC methods are as described above, except for the SPME exposition time, which was shorter (5 min) to avoid excessive overload of the fiber.

In agreement with the minimum reported standard guidelines suggested by the Metabolomics Standard Initiative, the most discriminatory features were putative annotated (Level 2) or putatively assigned to a chemical class (Level 3) [44] based on mass spectral similarities to the NIST 2011 mass spectral library, with a match score ≥ 800 (out of 1000) required for putative identifications. In addition to the MS similarity, the putative identification was also supported by the LRI in agreement (i.e., in the ± 15 range), with data reported using the same stationary phase [45] (if available). Unless confirmed by the LRI value, hydrocarbons were generally assigned as 'alkylated hydrocarbons', as only the chemical class of these compounds can be assigned considering their mass spectral fragmentation pattern and their location in the two-dimensional chromatogram.

2.5. Statistical analysis

All statistical analyses were performed using R v3.3.2 (R Foundation for Statistical Computing, Vienna, Austria). Prior to statistical analyses, the chromatographic area of compounds across chromatograms was normalized using probabilistic quotient normalization [46]. Variables were log-transformed, mean-centered, and unit-scaled prior to all statistical analyses. Random forest (RF)[47] was used to identify the most highly discriminatory volatile molecules and predict the class to which a leave-one-out cross validation (LOOCV) sample belonged. LOOCV was repeated 31 times, leaving out each sample (e.g., 8 PA⁺/RSV⁺, 8 PA⁻/RSV⁺, 8 PA⁺/RSV⁻, and 7 PA⁻/RSV⁻) once. The class probabilities were used to generate receiver operating characteristic (ROC) curves, and from these ROC curves, sensitivities, specificities, and AUROC curve were calculated. The optimal thresholds for class probabilities were calculated using Youden's J statistic [48], rather than the 0.5 cutoff that is traditionally applied to two-class classification problems. Mean decrease in accuracy (MDA) was used as the measure of variable importance. The Mann-Whitney U test [49] was used to compare the normalized area of volatile molecules between experimental groups (table 1), while a Student's t-test was used to compare class probabilities between groups.

3. Results and discussion

3.1. RSV and *P. aeruginosa* infections

Infections with RSV and/or *P. aeruginosa* were confirmed by RT-qPCR and dilution plating, respectively (figure 1). RSV transcripts were readily detected in both RSV-infected and co-infected respiratory epithelium (figure 1(A)), indicating that a productive RSV infection was achieved. In addition to RSV transcript detection, we also observed a strong antiviral response by the RSV-infected and co-infected respiratory epithelium, evidenced by upregulation of the gene encoding IFN- λ 1 (IFNL1, figure 1(B)). Similar to previous studies [23, 50], RSV co-infection of the respiratory epithelium enhanced *P. aeruginosa* biofilm biogenesis, as compared to *P. aeruginosa* alone (figure 1(C)). Together, these results indicate that the samples processed for volatile fingerprinting were suitable to serve as representative uninfected (PA⁻/RSV⁻), *P. aeruginosa*-infected (PA⁺/RSV⁻), RSV-infected (PA⁻/RSV⁺), and co-infected (PA⁺/RSV⁺) respiratory epithelium.

3.2 Volatile fingerprints of *P. aeruginosa* and RSV infections

Raw chromatographic data consisting of 762 features across the 31 samples of interest (8 PA⁺/RSV⁺, 8 PA⁻/RSV⁺, 8 PA⁺/RSV⁻, and 7 PA⁻/RSV⁻) were pre-processed to remove artifacts, resulting in a final data matrix consisting of 230 compounds plausibly derived from the biological specimens themselves.

We first sought to determine whether there was a subset of volatile metabolites that were significantly different in abundance between experimental groups. Forty-three features were identified as significantly different in at least one comparison and are reported in table 1, along with their putative identification (if possible). The abundance of each feature in the different pair-wise comparisons is reported in table 1. Arrow directions indicate the group in which the compound was more abundant, with '↑' indicating that the compound was significantly more abundant in the first group listed in the column heading, and '↓' indicating that the compound was significantly more abundant in the second group. Thirty-four of these 43 features were significantly different between PA⁺/RSV⁻ and PA⁻/RSV⁻, 19 between PA⁻/RSV⁺ and PA⁻/RSV⁻, and 16 between PA⁺/RSV⁺ and PA⁻/RSV⁻, of which only three (all alkylated hydrocarbons) were not overlapped with the features reported from the comparison between PA⁺/RSV⁻ and PA⁻/RSV⁻. Only six features were significantly different between PA⁺/RSV⁻ and PA⁻/RSV⁺, all more expressed in the former group, except one alkylated hydrocarbon. Notably, only one feature was significantly more expressed in PA⁺/RSV⁻ versus PA⁺/RSV⁺ (cyclohexanone), whereas five were significantly different in the comparison of PA⁻/RSV⁺ versus PA⁺/RSV⁺, all more expressed in the latter group. Seven of the putatively identified metabolites have been previously identified in the headspace of *P. aeruginosa* grown under in vitro conditions [51–57], three metabolites were previously identified in the headspace of cell line infected with human respiratory viruses [58], and one, 2-ethylhexanal, has been detected in the headspace of several cancer cell cultures [28].

3.3. Discriminatory ability of the volatile metabolite signature

We next sought to determine whether volatile metabolic fingerprints could discriminate between infected and uninfected CFBE cells. RF was used to assess the capability of volatile fingerprints to discriminate between: (I) *P. aeruginosa*-infected (including both PA⁺/RSV⁻ and PA⁺/RSV⁺) versus non-*P. aeruginosa*-infected (PA⁻/RSV⁻ and PA⁻/RSV⁺) cells, and (II) RSV-infected (including both PA⁻/RSV⁺ and PA⁺/RSV⁺) versus non-RSV-infected (PA⁺/RSV⁻ and PA⁻/RSV⁻) cells. ROC curves were generated using class probabilities for LOOCV samples (figure 2).

The results obtained from the first model (*P. aeruginosa* versus non-*P. aeruginosa*) yielded an AUROC of 0.850, with a sensitivity of 0.938 and specificity of 0.800 at an optimal class probability cutoff of 0.544 (figure 2(a), left). In contrast, the ability to discriminate between RSV-infected and non-RSV-infected cells was approximately random, with an AUROC of 0.431, and optimal sensitivity and specificity of 0.500 and 0.533, respectively (figure 2(b), right). Taken together, these findings suggest that under the experimental conditions employed in the present study, infection of CFBE with *P. aeruginosa* produces a detectable volatile molecular fingerprint, while infection of CFBE with RSV does not.

Table1. List of volatile metabolites significantly different between experimental groups, along with their putative identification. The direction of the arrows indicate the group in which the compound was significantly more abundant. '↑' indicates that the compound was significantly more abundant in the first group listed in the column heading, and '↓' indicates that the compound was significantly more abundant in the second group.

#	Compound	Class	Formula	CAS	Similarity	LRI _{Exp}	LRI _{Lit}	¹ t _R (min:s)	² t _R (s)	References	PA ⁻ /RSV ⁻ versus PA ⁺ /RSV ⁻	PA ⁻ /RSV ⁻ versus PA ⁻ /RSV ⁺	PA ⁻ /RSV ⁻ versus PA ⁺ /RSV ⁺	PA ⁺ /RSV ⁻ versus PA ⁻ /RSV ⁺	PA ⁺ /RSV ⁻ versus PA ⁺ /RSV ⁺	PA ⁻ /RSV ⁺ versus PA ⁺ /RSV ⁺
1	2-Propenal	Ald	C ₃ H ₄ O	107-02-8	855	538	523	6:00	1.0		↓		↓			
2 ^a	Acetone	Ket	C ₃ H ₆ O	67-64-1	978	545	530	6:15	0.8	[51,60]	↓	↓	↓	↑		↓
3	2-methyl-pentane	Hyd	C ₆ H ₁₄	107-83-5	941	570	564	7:12	0.6	[58]	↑	↑				
4	Unknown	Ald				595		8:08	0.7		↓					
5	Alkylated hydrocarbons	Hyd				627		9:27	0.7			↑				
6	Butanal	Ald	C ₄ H ₈ O	123-72-8	863	627	629	9:28	0.8	[51,57,60]	↓					
7 ^a	2-Butanone	Ket	C ₄ H ₈ O	78-93-3	965	629	637	9:32	1.00	[51-57,59,60]	↓		↓			↓
8	Unknown	S-Com				650		10:28	1.5		↑					
9	Tetrahydrofuran	Het-Cyc	C ₄ H ₈ O	109-99-9		651	655	10:31	0.7	[58]	↓	↓				
10 ^a	3-methylbutanal	Ald	C ₅ H ₁₀ O	590-86-3	924	693	694	12:19	0.8	[54-56]	↓			↑		↓
11 ^a	2-methylbutanal	Ald	C ₅ H ₁₀ O	96-17-3	850	701	—	12:41	0.7	[54,55,57]	↓			↑		
12	Alkylated hydrocarbons	Hyd				753		15:24	0.6				↑			
13	Alkylated hydrocarbons	Hyd				760		15:46	0.6				↑			
14	Alkylated hydrocarbons	Hyd				767		16:06	0.6		↑	↑	↑			
15	4-methyl-2-pentanone	Ket	C ₆ H ₁₂ O	108-10-1	850	780	783	16:46	1.00			↑				
16	Alkylated hydrocarbons	Hyd				791		17:21	0.8			↓				
17	Alkylated hydrocarbons	Hyd				822		19:02	0.6		↑	↑	↑			
18	Alkylated hydrocarbons	Hyd				846		20:17	0.7		↑	↑	↑			
19	Alkylated hydrocarbons	Hyd				858		20:56	0.6		↑	↑	↑			
20	2-methyl-octane	Hyd	C ₉ H ₂₀	3221-61-2	862	864	873	21:14	0.6	[58]	↑	↑	↑			
21	Alkylated hydrocarbons	Hyd				874		21:48	0.6		↑	↑	↑			
22	Cyclohexanone	Ket	C ₆ H ₁₀ O	108-94-1	910	955	957	25:58	0.9		↓				↑	
23	Alkylated hydrocarbons	Hyd				977		27:05	0.6		↑	↑	↑			
24 ^a	2-ethylhexanal	Ald	C ₈ H ₁₆ O	123-05-7	918	993	—	27:54	0.8	[29]						↓
25	Alkylated hydrocarbons	Hyd				1088		32:35	0.6		↓					
26	Alkylated hydrocarbons	Hyd				1091		32:44	0.6					↓		
27	Alkylated hydrocarbons	Hyd				1097		33:02	0.6		↑	↑	↑			
28 ^a	Undecane	Hyd	C ₁₁ H ₂₄	1120-21-4	872	1102	1100	33:14	0.7	[56]	↑					
29 ^a	Alkylated hydrocarbons	Hyd				1115		33:50	0.7		↑					
30	Alkylated hydrocarbons	Hyd				1121		34:08	0.9		↓	↓				
31	Unknown	Ket				1137		34:50	1.3		↓	↓	↓			
32	Alkylated hydrocarbons	Hyd				1159		35:51	0.7		↓					

Table1. (Continued.)

#	Compound	Class	Formula	CAS	Similarity	LRI _{Exp}	LRI _{Lit}	¹ t _R (min:s)	² t _R (s)	References	PA ⁻ /RSV ⁻ versus PA ⁺ /RSV ⁻	PA ⁻ /RSV ⁻ versus PA ⁻ /RSV ⁺	PA ⁻ /RSV ⁻ versus PA ⁺ /RSV ⁺	PA ⁺ /RSV ⁻ versus PA ⁻ /RSV ⁺	PA ⁺ /RSV ⁻ versus PA ⁺ /RSV ⁺	PA ⁻ /RSV ⁺ versus PA ⁺ /RSV ⁺
33 ^a	Alkylated hydrocarbons	Hyd				1175		36:33	0.6		↓			↑		
34	Alkylated hydrocarbons	Hyd				1214		38:17	0.6					↑		↓
35	Alkylated hydrocarbons	Hyd				1294		41:42	0.6		↑	↑				
36	Alkylated hydrocarbons	Hyd				1301		42:02	0.6		↑	↑				
37	Alkylated hydrocarbons	Hyd				1319		42:44	0.6		↓					
38	Alkylated hydrocarbons	Hyd				1325		42:58	0.6		↑	↑				
39	Alkylated hydrocarbons	Hyd				1335		43:21	0.7		↑					
40 ^a	Alkylated hydrocarbons	Hyd				1340		43:34	0.6		↑					
41	Alkylated hydrocarbons	Hyd				1496		49:32	0.6		↑		↑			
42	Alkylated hydrocarbons	Hyd				1541		51:08	0.6				↑			
43	Alkylated hydrocarbons	Hyd				1567		52:04	0.7		↑					

^a MDA > 0.01 for the comparison of *P. aeruginosa*-infected versus non-*P. aeruginosa*-infected cells.




Figure 1. RSV and *P. aeruginosa* infection of CF respiratory epithelial cells. (A) ΔC_T values for RT-qPCR of infected CFBE cells with RSV N gene primers, normalized to GAPDH. Y axis inverted to represent that lower numbers (including more negative) indicate greater abundance of RNA. Data represent the mean and standard deviation, statistical comparison by paired ANOVA with Sidak correction for multiple comparisons. (B) Fold change in IFNL1 expression for infected CFBE cells as determined by RT-qPCR, normalized to GAPDH and compared to uninfected control cells. Data represent the mean, statistical comparison to uninfected control by paired ANOVA with Dunnett correction for multiple comparisons. (C) CFU of *P. aeruginosa* growing in mucosal biofilms associated with infected CFBE cells. Data represent the mean, statistical comparison by paired t-test. *: $p < 0.05$, ***: $p < 0.001$, ****: $p < 0.0001$.




Figure 2. Receiver operating characteristic (ROC) curves for the discrimination between: (A) *P. aeruginosa*-infected (PA⁺/RSV⁻ and PA⁺/RSV⁺) versus non-*P. aeruginosa*-infected (PA⁻/RSV⁻ and PA⁻/RSV⁺) cells, and (B) RSV-infected (PA⁻/RSV⁺ and PA⁺/RSV⁺) versus non-RSV-infected (PA⁻/RSV⁻ and PA⁺/RSV⁻), cells generated using random forest. *Optimal sensitivity and specificity of each statistical model are calculated at the given class prediction cutoff (ranging from 0 to 1).

The class probabilities for each sample in the comparison of *P. aeruginosa* versus non-*P. aeruginosa*-infected CFBE were plotted, with 0 indicating non-*P. aeruginosa*-infected, and 1 indicating *P. aeruginosa*-infected (figure 3). Within the *P. aeruginosa*-infected group, there was no significant difference in class probabilities between PA⁺/RSV⁻ and PA⁺/RSV⁺ ($p = 0.71$). It is interesting, however, that the class probabilities for PA⁻/RSV⁺ were significantly different from both PA⁻/RSV⁻ ($p = 0.03$) as well as PA⁺/RSV⁻ ($p = 0.02$). This finding suggests that RSV singular infection results in a volatile molecular fingerprint that shares attributes with both PA⁻/RSV⁻ as well as PA⁺/RSV⁻, possibly resultant from a general host response to infection. In contrast to the comparison of *P. aeruginosa*-infected versus non-*P. aeruginosa*-infected cells, there were no significant differences in class probabilities between groups for the comparison of RSV-infected versus non-RSVinfected cells (supplementary figure S1 is available online at stacks.iop.org/JBR/12/046001/mmedia).




Figure 3. Class probabilities for LOOCV samples ($n = 31$) for the comparison of *P. aeruginosa*-infected versus non-*P. aeruginosa*-infected cells. Points towards the top of the plot indicate a higher probability of classifying as *P. aeruginosa*-infected, while points towards the bottom of the plot indicate a higher probability of classifying as non-*P. aeruginosa*-infected. The horizontal dotted line corresponds to optimal sensitivity/specificity cutoff (0.544). Wide bars represent median probability for each class, while narrow bars represent 25th and 75th percentiles.




Figure 4. Boxplot of the most discriminatory features (MDA > 0.01) for discrimination between *P. aeruginosa*-infected versus non-*P. aeruginosa*-infected cells. *: $p < 0.05$. (a) Data were mean-centered and scaled before plotting. Identification as per table 1.

3.4. Most discriminatory metabolites and their possible origin

For the comparison of *P. aeruginosa*-infected versus non-*P. aeruginosa*-infected cells, volatile molecules were ranked according to their discriminatory ability, as defined by their MDA (a measure of variable importance). The intensity profile of the most discriminatory molecules (MDA > 0.01) are visualized in figure 4. Six of these nine were putatively identified [two ketones (acetone and 2-butanone), three aldehydes (3-

methylbutanal, 2-methylbutanal, and 2-ethylhexanal), one hydrocarbon (undecane)] and three compounds were generally assigned as alkylated hydrocarbons (table1).

The chemical classes (ketones, aldehydes, hydrocarbons) reported herein in culture headspace can be plausibly attributed to lipid oxidation pathways. Acetone and 2-butanone derive from the decarboxylation of β -keto acids, and have been reported as important markers of *P. aeruginosa* elsewhere [51–57, 59, 60]. Aldehydes have been related to lipid peroxidation during inflammation [61], and 3-methylbutanal and 2-methylbutanal have been also reported as key intermediate in the catabolism of amino acids, such as leucine [62, 63]. Aliphatic hydrocarbons (e.g. undecane) may be derived from the metabolism of fatty acids, which are converted to aldehydes due to the activity of acyl-CoA reductase, and enzymatically decarboxylated to hydrocarbons [64]. A preponderance of hydrocarbons were also highlighted in the headspace of human and murine epithelial cells infected with RSV and Influenza A, respectively [58]. Indeed, it has been shown that viral infection increases the production of reactive oxygen species, in part through a NAD (P)H oxidase-dependent mechanism [65], which is associated with the formation of hydrocarbons.

3.5. Analysis of the headspace of *P. aeruginosa* during growth in MEM

Finally, we hypothesized that a subset of the nine metabolites identified as highly discriminatory between *P. aeruginosa*-infected versus non-*P. aeruginosa*-infected CFBE resulted from either the consumption or production of metabolites by the bacterium itself. To test this, *P. aeruginosa* was grown as a biofilm in MEM in the absence of respiratory epithelium. Of the nine compounds selected, six were found in the headspace of *P. aeruginosa* grown alone, namely acetone, 2-butanone, 2-methylbutanal, undecane, and two hydrocarbons (#29 and #40). However, none of these differed significantly in abundance between *P. aeruginosa* in MEM and sterile media (MEM alone), suggesting that the selected metabolites likely result from the interaction of *P. aeruginosa* with the CFBE cells, or are produced in higher quantity during the interaction between *P. aeruginosa* and CFBE cells. Three compounds, 3-methylbutanal, 2-ethylhexanal and a hydrocarbon (#33), were not found in the headspace of *P. aeruginosa* grown only in media, suggesting that they originate from the interaction of *P. aeruginosa* with CFBE cells, or from the response of CFBE cells to the presence of *P. aeruginosa*.

3.6. Study strengths and limitations

The present study represents a first attempt at evaluating the volatile metabolic signatures of both singular *P. aeruginosa* and RSV infection, as well as *P. aeruginosa* RSV co-infection, in the setting of *in vitro* CFBE cell co-culture. The use of CFBE cell culture represents a more clinically significant growth environment relative to growth in nutrient-rich *in vitro* environments. This, in turn, can provide insight for future *in vivo* experimental models and inform translational studies in patient populations. Furthermore, our evaluation of *P. aeruginosa* grown in MEM allows us to hypothesize about the origins of these metabolites, although further experiments are needed to determine whether these discriminatory metabolites arise from metabolism of alternate substrates by *P. aeruginosa* in the presence of CFBE, and/or the response of CFBE to the presence of *P. aeruginosa*.

With respect to study limitations, we acknowledge that we consider only a single, reference strain (PAO1), which may not be metabolically representative of all possible *P. aeruginosa* strains. Furthermore, we were able to analyze only a small volume (500 μ l) per replicate, and that this may have contributed to a relatively

weak signal intensity, possibly below the detection limit for a subset of analytes. This, in turn, may have contributed to our inability to identify a robust volatile metabolic signature associated with RSV infection. Moreover, the volatile profiles obtained do not necessarily mirror the real profile present in the headspace of the sample, since it is mediated by the specific selectivity of the SPME fiber (PDMS/Car/DVB) used. The identification of the discriminatory compounds was putative and the confirmation of their identity with analytical standards should be confirmed in future studies. Finally, it is important to consider that the CFBE cell system models the initial interaction (6 h) of *P. aeruginosa* with the respiratory epithelium. It is therefore possible that a longer interaction time might yield to a more robust signal and altered metabolite detection as the infection persists.

4. Conclusions

In the present study, we demonstrate that volatile metabolites can be used to discriminate between *P. aeruginosa* (PAO1) infected and non-*P. aeruginosa*-infected respiratory epithelium. Although weak and non-discriminatory, a signature related to the RSV singular infection can be observed (see figure 3), while the volatile signature of co-infected samples (PA⁺/RSV⁺) is dominated by the signature produced by *P. aeruginosa*. The contribution of the host response to the abundance of some of these discriminatory metabolites can be hypothesized, since their abundances were significantly different from the control when RSV singular infection was present (acetone, undecane, and a hydrocarbon (#29)). Furthermore, the formation of 2-butanone, 3-methylbutanal, and 2-ethylhexanal can be associated with the specific interaction between *P. aeruginosa* and the CFBE cells, as these metabolites were not detected in the headspace of *P. aeruginosa* grown as a biofilm in the absence of CFBE.

Acknowledgments

Financial support for this work was provided by the Hitchcock Foundation and the National Institute of Health (NIH, Project # 1R21AI12107601). CAR was supported by the Burroughs Wellcome Fund Institutional Program Unifying Population and Laboratory Based Sciences, awarded to Dartmouth College (Grant # 1014106), and a T32 training grant (T32LM012204, PI: Christopher I Amos). JAM was supported by the Cystic Fibrosis Foundation (MELVIN15F0) and a T32 training grant (T32AI049820, PI: Neal A DeLuca). JMB was supported by the Cystic Fibrosis Foundation (BOMBER14G0) and National Institutes of Health (R01HL123771).

ORCIDiDs

Giorgia Purcaro <https://orcid.org/0000-0002-8235-9409>

Christiaan A Rees <https://orcid.org/0000-0003-1896-5348>

Jane E Hill <https://orcid.org/0000-0003-3725-3266>

References

- [1] WHO 2014 Media centre the top 10 causes of death *Fact sheet N°310* (Updated May 2014) 2012–4 www.who.int/gho/mortality_burden_disease/causes_death/top_10/en/
- [2] UNICEF 2015 Levels and trends in child mortality *New York UNICEF 1–30* www.unicef.org/publications/files/Child_Mortality_Report_2015_Web_9_Sept_15.pdf

- [3] Jain S *et al* 2015 Community-acquired pneumonia requiring hospitalization among US children *New Engl. J. Med.* [372 835–45](#)
- [4] Jain S *et al* 2015 Community-acquired pneumonia requiring hospitalization among US adults *New Engl. J. Med.* [373 415–27](#)
- [5] Peters B M, Jabra-Rizk M A, O'May G A, William Costerton J and Shirtliff M E 2012 Polymicrobial interactions: impact on pathogenesis and human disease *Clin. Microbiol. Rev.* [25 193–213](#)
- [6] Bosch A A T M, Biesbroek G, Trzcinski K, Sanders E A M and Bogaert D 2013 Viral and bacterial interactions in the upper respiratory tract *PLoS Pathogens* [9 e1003057](#)
- [7] Melvin J A and Bomberger J M 2016 Compromised defenses: exploitation of epithelial responses during viral-bacterial co-infection of the respiratory tract *PLoS Pathogens* [12 1–7](#)
- [8] Caliendo A M *et al* 2013 Better tests, better care: improved diagnostics for infectious diseases *Clin. Infect. Dis.* [57 S139–70](#)
- [9] Hament J M, Aerts P C, Fleer A, Van Dijk H, Harmsen T, Kimpen J L L and Wolfs T F W 2005 Direct binding of respiratory syncytial virus to pneumococci: a phenomenon that enhances both pneumococcal adherence to human epithelial cells and pneumococcal invasiveness in a murine model *Pediatr. Res.* [58 1198–203](#)
- [10] McCullers J A 2006 Insights into the interaction between influenza virus and pneumococcus *Clin. Microbiol. Rev.* [19 571–82](#)
- [11] Avadhanula V, Rodriguez C A, DeVincenzo J P, Wang Y, Webby R J, Ulett G C and Adderson E E 2006 Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner *J. Virol.* [80 1629–36](#)
- [12] Stark J M, Stark M A, Colasurdo G N and LeVine A M 2006 Decreased bacterial clearance from the lungs of mice following primary respiratory syncytial virus infection *J. Med. Virol.* [78 829–38](#)
- [13] van der Sluijs K F, van Elden L J R, Nijhuis M, Schuurman R, Pater J M, Florquin S, Goldman M, Jansen H M, Lutter R and van der Poll T 2004 IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection *J. Immunol.* [172 7603–9](#)
- [14] Frayman K B, Armstrong D S, Grimwood K and Ranganathan S C 2017 The airway microbiota in early cystic fibrosis lung disease *Pediatr. Pulmonol.* [52 1384–404](#)
- [15] Wat D, Gelder C, Hibbitts S, Cafferty F, Bowler I, Pierrepont M, Evans R and Doull I 2008 The role of respiratory viruses in cystic fibrosis *J. Cyst. Fibros.* [7 320–8](#)
- [16] Smyth A R, Smyth R L, Tong C Y W, Hart C A and Heaf D P 1995 Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis *Arch. Dis. Child.* [73 117–20](#)
- [17] Collinson J, Nicholson K G, Cancio E, Ashman J, Ireland D C, Hammersley V, Kent J and Callaghan C O 1996 Effects of upper respiratory tract infections in patients with cystic fibrosis *Thorax* [51 1115–22](#)
- [18] Hiatt P W, Grace S C, Kozinetz C A, Raboudi S H, Treece D G, Taber L H, Piedra P A and Objective A 2018 Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis *Pediatrics* [103 619–26](#)
- [19] Brownlee J W and Turner R B 2008 New developments in the epidemiology and clinical spectrum of rhinovirus infections *Curr. Opin. Pediatr.* [20 67–71](#)
- [20] Petersen N T, Hoiby N, Mordhorst C H, Lind K, Flensburg E W and Bruun B 1981 Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma-possible synergism with *Pseudomonas aeruginosa* *Acta Paediatr. Scand.* [70 626–8](#)

- [21] Van Ewijk B E, Van Der Zalm M M, Wolfs T F W and Van Der Ent C K 2005 Viral respiratory infections in cystic fibrosis *J. Cyst. Fibros.* **4** 31–6
- [22] Courtney J M, Bradley J, Mccaughan J, T M O'Connor , Shortt C, Bredin C P, Bradbury I and Elborn J S 2007 Predictors of mortality in adults with cystic fibrosis *Pediatr. Pulmonol.* **42** 525–32
- [23] Hendricks M R, Lashua L P, Fischer D K, Flitter B A, Eichinger K M, Durbin J E, Sarkar S N, Coyne C B, Empey K M and Bomberger J M 2016 Respiratory syncytial virus infection enhances *Pseudomonas aeruginosa* biofilm growth through dysregulation of nutritional immunity *Proc. Natl Acad. Sci.* **113** 1642–7
- [24] Sethi S, Nanda R and Chakraborty T 2013 Clinical application of volatile organic compound analysis for detecting infectious diseases *Clin. Microbiol. Rev.* **26** 462–75
- [25] Zhu J, Bean H D, Jimenez-Diaz J and Hill J E 2013 Secondary electrospray ionization-mass spectrometry (SESI-MS) breathprinting of multiple bacterial lung pathogens, a mouse model study *J. Appl. Physiol.* **114** 1544–9
- [26] Zhu J, Bean H D, Wargo M J, Leclair L W and Hill J E 2014 Detecting bacterial lung infections: *in vivo* evaluation of *in vitro* volatile fingerprints *J. Breath Res.* **7** 16003
- [27] Zhu J, Jiménez-Díaz J, Bean H D, Daphtary N A, Aliyeva M I, Lundblad L K A and Hill J E 2013 Robust detection of *P. aeruginosa* and *S. aureus* acute lung infections by secondary electrospray ionization-mass spectrometry (SESI-MS) breathprinting: from initial infection to clearance *J. Breath Res.* **7** 37106
- [28] Filipiak W, Mochalski P, Filipiak A, Ager C, Cumeras R, Davis C E, Agapiou A, Unterkofler K and Troppmair J 2016 A compendium of volatile organic compounds (VOCs) released by human cell lines *Curr. Med. Chem.* **23** 2112–31
- [29] Filipiak W *et al* 2015 Breath analysis for *in vivo* detection of pathogens related to ventilator-associated pneumonia in intensive care patients: a prospective pilot study Breath analysis for *in vivo* detection of pathogens related to ventilator-associated pneumonia in intensive *J. Breath Res.* **9** 16004
- [30] Fowler S J, Basanta-sanchez M, Xu Y, Goodacre R and Dark P M 2015 Surveillance for lower airway pathogens in mechanically ventilated patients by metabolomic analysis of exhaled breath: a case-control study *Thorax* **70** 320–5
- [31] Schnabel R, Fijten R, Smolinska A, Dallinga J and Van Schooten F J 2015 Analysis of volatile organic compounds in exhaled breath to diagnose ventilator-associated pneumonia *Sci. Rep.* **5** 17179
- [32] Sweeney T E, Shidham A, Wong H R, Khatri P, Alto P and Alto P 2016 A comprehensive time-course-based multicohort analysis of sepsis and sterile inflammation reveals a robust diagnostic gene set *Sci. Transl. Med.* **7** 287ra71
- [33] Sweeney T and Purvesh K 2015 Comprehensive validation of the FAIM3:PLAC8 ratio in time matched public gene expression data *Am. J. Respir. Crit. Care Med.* **192** 1260–1
- [34] McHugh L *et al* 2015 A molecular host response assay to discriminate between sepsis and infection-negative systemic inflammation in critically ill patients: discovery and validation in independent cohorts *PLoS Med.* **12** 1–35
- [35] Scicluna B P *et al* 2015 A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission *Am. J. Respir. Crit. Care Med.* **192** 826–35
- [36] Hu X, Yu J, Crosby S D and Storch G A 2013 Gene expression profiles in febrile children with defined viral and bacterial infection *Proc. Natl Acad. Sci.* **110** 12792–7
- [37] Zaas A K *et al* 2013 A HOST-BASED RT-PCR gene expression signature to identify acute respiratory viral infection *Sci. Transl. Med.* **5** 203ra126

- [38] Suarez N M, Bunsow E, Falsey A R, Walsh E E, Mejias A and Ramilo O 2015 Superiority of transcriptional profiling over procalcitonin for distinguishing bacterial from viral lower respiratory tract infections in hospitalized adults *J. Infect. Dis.* [212 213–22](#)
- [39] Delneste Y, Beauvillain C and Jeannin P 2007 Innate immunity: structure and function of TLRs *Med. Sci.* [23 67–73](#)
- [40] Medzhitov R and Janeway C A J 1997 Innate immunity: minireview the virtues of a nonclonal system of recognition *Cell* [91 295–8](#)
- [41] Medzhitov R and Janeway C J 2000 Innate immune recognition: mechanisms and pathways *Immunol. Rev.* [173 89–97](#)
- [42] Sung R Y, Hui S H, Wong C K, Lam C W and Yin J 2001 A comparison of cytokine responses in respiratory syncytial virus and influenza A infections in infants *Eur. J. Pediatr.* [160 117–22](#)
- [43] d'Acampora Zellner B, Bicchi C, Dugo P, Rubiolo P, Dugo G and Mondello L 2008 Linear retention indices in gas chromatographic analysis: a review *Flavour Fragr. J.* [23 297](#)
- [44] Sumner L W, Samuel T, Noble R, Gmbh S D, Barrett D, Beale M H and Hardy N 2007 Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI) *Metabolomics* [3 211–21](#)
- [45] Schallschmidt K, Becker R, Jung C, Bremser W, Walles T, Neudecker J, Leschber G, Frese S and Nehls I 2016 Comparison of volatile organic compounds from lung cancer patients and healthy controls-challenges and limitations of an observational study *J. Breath Res.* [10 46007](#)
- [46] Dieterle F, Ross A, Schlotterbeck G and Senn H 2006 Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabolomics *Anal. Chem.* [78 4281–90](#)
- [47] Breiman L 2001 Random forests *Mach. Learn.* [45 5–32](#)
- [48] Ruopp M D, Perkins N J, Whitcomb B W and Schisterman Enrique F 2008 Youden index and optimal cut- point estimated from observations affected by a lower limit of detection *Biometrical J.* [50 419–30](#)
- [49] Mann H B and Whitney D R 1947 On a test of whether one of two random variables is stochastically larger than the other *Ann. Math. Stat.* [18 50–60](#)
- [50] Melvin J A, Lashua L P, Kiedrowski M R, Yang G, Deslouches B, Montelaro R C and Bomberger J M 2016 Simultaneous antibiofilm and antiviral activities of an engineered antimicrobial mSphere [1 e00083](#)
- [51] Shestivska V, Spanel P, Dryahina K, Sovova K, Smith D, Musilek M and Nemeč A 2012 Variability in the concentrations of volatile metabolites emitted by genotypically different strains of *Pseudomonas aeruginosa* *J. Appl. Microbiol.* [113 701–13](#)
- [52] Bean H D, Rees C A and Hill J E 2016 Comparative analysis of the volatile metabolomes of *Pseudomonas aeruginosa* clinical isolates *J. Breath Res.* [10 47102](#)
- [53] Labows J N, Mcginley K J, Webster G U Y F and Leyden J J 1980 Headspace analysis of volatile metabolites of *Pseudomonas aeruginosa* and related species by gas chromatography- mass spectrometry *J. Clin. Microbiol.* [12 521–6](#)
- [54] Filipiak W, Sponring A, Baur M M, Filipiak A, Ager C, Wiesenhofer H, Nagl M, Troppmair J and Amann A 2012 Molecular analysis of volatile metabolites released specifically by *Staphylococcus aureus* and *Pseudomonas aeruginosa* *BMC Microbiol.* [12 113](#)
- [55] Boots A W 2014 Identification of microorganisms based on headspace analysis of volatile organic compounds by gas chromatography—mass spectrometry *J. Breath Res.* [8 27106](#)

- [56] Zechman M, Aldinger S and Labows J 1986 Characterization of pathogenic bacteria by automated headspace concentration- gas chromatography *J. Chromatogr.* **377** 49–57
- [57] Neerinx A H *et al* 2016 Identification of *Pseudomonas aeruginosa* and *Aspergillus fumigatus* mono- and co-cultures based on volatile biomarker combinations identification of *Pseudomonas aeruginosa* and *Aspergillus fumigatus* mono- and co-cultures based on volatile biomarker combinat *J. Breath Res.* **10** 16002
- [58] Purcaro G, Rees C A, Wieland-alter W F, Schneider M J, Wang X, Stefanuto P, Wright P F, Enelow R I and Hill J E 2018 Volatile fingerprinting of human respiratory viruses from cell culture *J. Breath Res.* **12** 26015
- [59] Rudzinski C M, Herzig-marx R, Lin J, Szpiro A, Johnson B and Street W 2004 Pathogen detection using headspace analysis *Scientific Conf. on Chemical and Biological Defense Research*
- [60] Dryahina K, Sovová K, Nemeč A and Španěl P 2016 Differentiation of pulmonary bacterial pathogens in cystic fibrosis by volatile metabolites emitted by their *in vitro* cultures: *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Stenotrophomonas maltophilia* and the *Burkholderia cepacia* complex differentia *J. Breath Res.* **10** 37102
- [61] Forman H J 2010 Reactive oxygen species and alpha, beta- unsaturated aldehydes as second messengers in signal transduction *Ann. NY Acad. Sci.* **1203** 35–44
- [62] Schulz S and Dickschat J S 2007 Bacterial volatiles: the smell of small organisms *Nat. Prod. Rep.* **24** 814–42
- [63] Marilley L and Casey M G 2004 Flavours of cheese products: metabolic pathways, analytical tools and identification of producing strains *Int. J. Food Microbiol.* **90** 139–59
- [64] Ladygina N, Dedyukhina E G and Vainshtein M B 2006 A review on microbial synthesis of hydrocarbons *Process Biochem.* **41** 1001–14
- [65] Hosakote Y M, Liu T, Castro S M, Garofalo R P and Casola A 2009 Respiratory syncytial virus induces oxidative stress by modulating antioxidant enzymes *Am. J. Respir. Cell Mol. Biol.* **41** 348–57